RET and glioblastoma: These findings demonstrate that mTC1 has little effect on viability in GBM and HeLa cell lines at lower concentrations, with only moderate reductions at higher concentrations, suggesting a potential for targeted therapeutic use with minimal cytotoxic effects at lower doses.